Trial Profile
A double-blind, dose-escalation trial evaluating the safety and immunogenicity of a human papillomavirus (HPV) type 16 (HPV16) L1 VLP vaccine in healthy adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine (Primary) ; Alum; MF 59
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 05 Nov 2010 New trial record.